Enhancing the efficiency of oncolytic vaccinia virus for ovarian cancer treatment
Drymiotou, S.; Queval, C. J.; Tyson, K. E.; Sheach, L. A.; Postigo, A.; Rosa, I. D.; Howell, M.; McNeish, I. A.; Way, M.
Show abstract
Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 ({Delta}VF) to induce death of ID8 Trp53-/- murine ovarian cancer cells. We identified a class of tubulin polymerisation inhibitors including vinorelbine. The combination of vinorelbine and vaccinia induces ID8 Trp53-/- cell death via apoptosis. In a syngeneic mouse model of high grade serous ovarian carcinoma, {Delta}VF virus lacking the viral thymidine kinase (TK), armed with GM-CSF and expressing NeonGreen ({Delta}VFTK-NG-GM-CSF) is tumour specific. A combination of the {Delta}VFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests vinorelbine is a promising agent to combine with oncolytic vaccinia virus approaches for the management of ovarian cancer.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 95%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 94%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 94%
Similar papers in this journal
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2 95%
- BiP/GRP78 is a pro-viral factor for diverse dsDNA viruses that promotes the survival and proliferation of cells upon KSHV infection 94%
- Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells 94%
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
- The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern 95%
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys 94%
Similar papers in this journal
- Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases 94%
- ZEB1, a novel regulator of Junctional Adhesion Molecule A, impacts sensitivity of pancreatic cancer-associated fibroblasts to oncolytic reovirus 92%
- Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells 91%
Similar papers in this journal
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles 94%
- A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening 92%
- An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.